(Stroke. 1999;30:1256-1262.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, University of Ulm (Germany).
Correspondence to Dr Matthias W. Riepe, Department of Neurology, University of Ulm, Steinhövelstr 1, D-89075 Ulm, Germany. E-mail matthias.riepe{at}medizin.uni-ulm.de
| Abstract |
|---|
|
|
|---|
MethodsPopulation spike amplitude (PSA) and NADH were measured during hypoxic hypoxia and recovery in hippocampal slices from untreated control animals (C slices) and slices prepared from animals pretreated in vivo with a single intraperitoneal injection of 3-nitropropionate (3NP) (3NP slices) or acetylsalicylate (ASA) (ASA slices).
ResultsPosthypoxic recovery of PSA was dose dependent in 3NP slices from males, with maximal recovery on pretreatment attained with 20 mg/kg 3NP (82±32% [mean±SD]; C slices, 38±29%; P<0.01). PSA recovered to 17±12% in C slices during proestrus, 43±23% during estrus, and 63±44% during diestrus. In 3NP slices, recovery of PSA increased to 57±36% (P<0.05) during proestrus. Hypoxic tolerance was not increased in other stages of the estrus cycle. Hypoxic NADH increase during proestrus declined from 212±76% in C slices to 133±11% in 3NP slices (P<0.05). Recovery of PSA in ASA slices was 75±36% (P<0.01 versus control) in males and 48±34% during proestrus (P<0.05 versus ASA slices from males).
ConclusionsPrimary and induced hypoxic tolerance are endogenously modulated during the estrus cycle. Differences in hypoxic oxidative energy metabolism mediate part of the differential tolerance. Experimental and clinical therapeutic strategies against cerebral ischemia/hypoxia need to consider sex-related dependence.
Key Words: aspirin gender hypoxia neuroprotection mice
| Introduction |
|---|
|
|
|---|
Under appropriate conditions of time interval and dosage, a mild ischemic challenge of central nervous system tissue increases primary hypoxic tolerance and induced hypoxic tolerance by ischemic preconditioning.13 14 15 Chemical preconditioning is a recently developed practical strategy that allows induction of hypoxic tolerance in the central nervous system with mild cellular hypoxia as a result of drug treatment,16 17 eg, by 3-nitropropionate (3NP). Increased hypoxic tolerance is associated with improved energy metabolism during hypoxia, decreased posthypoxic free radical production, im- proved posthypoxic morphology, and preserved posthypoxic neuronal function.16 17 18
Ischemic preconditioning is already used in clinical practice and renders heart muscle cells more tolerant against ischemia during coronary angioplasty.19 Recently, it was suggested that chemical preconditioning also is unknowingly already in use.20 However, it has not yet been investigated whether ischemic or chemical preconditioning is useful to increase hypoxic tolerance in females as well.
Currently, the same strategies are in use for secondary stroke prevention in males and females. However, the most frequently used drug, acetylsalicylic acid (ASA), seems to have a differential benefit in males and females.21 Since inhibition of platelet aggregation by ASA is similar in males and females,22 inhibition of platelet aggregation cannot explain this observation.
The goal of the present study was (1) to investigate primary hypoxic tolerance in females during the estrus cycle and (2) to determine whether increased hypoxic tolerance by chemical preconditioning is a potential therapeutic strategy in females.
| Materials and Methods |
|---|
|
|
|---|
The estrus cycle was determined in female mice as described by Allen.24 In brief, the stages of the estrus cycle can be determined by analyzing the number and type of cells in the vaginal smear of the mice.
Further treatment for investigation of hypoxic hypoxia and chemical hypoxia was performed as described previously.16 17 18 Electrophysiological measurements were performed in the recording chamber (see below). Procedures followed institutional guidelines.
Electrophysiological Recordings
Recording of population spike amplitude (PSA) was
performed as previously described.17 18 In brief, slices
were transferred to a recording chamber after preincubation.
The recording chamber was perfused with Ringer's solution at 6
mL/min through a peristaltic pump. Slices with PSA <2 mV were not
included in the analysis. On stabilization of PSA, Ringer's
solution made hypoxic by bubbling with 95% N2
and 5% CO2
(PO2 in the recording chamber
<10 kPa after 5 minutes of perfusion with hypoxic Ringer's solution;
for detailed time course of PO2 in
the recording chamber, see Reference 2525 ) superfused the slices
for 15 minutes. After 15 minutes of hypoxia, slices were
superfused with oxygenated Ringer's solution until the end
of the experiment. Schaffer collaterals were synaptically
activated at 0.1 Hz by bipolar electrodes placed in hippocampal
region CA3. Population spikes were recorded in hippocampal region
CA1, and analysis was performed as described
previously.17 18
Fluorometric NADH Recordings
A pulsed nitrogen laser (excitation wavelength=337
nm, 30 µJ; LM 302, Laser Labor Adlershof) was used to induce
fluorescence.26 High spatial resolution for
excitation and detection was obtained by coupling the laser light into
an optical quartz fiber (diameter, 200 µm) that guides the
excitation light to the probe and the fluorescence light back
to the detector. A dichroic mirror separates the scattered excitation
light and the fluorescence light. A narrow band-pass filter,
centered at 460 nm (maximum of NADH fluorescence), is used for
the spectral resolution. A photomultiplier is used as detector, and an
electronic gate provides the time resolution of the signal. Data
acquisition is controlled by a standard PC. All results are displayed
online.
Statistical Analysis
Each experiment was conducted with 4 to 6 slices from 2 to 3
animals. Statistical testing was performed by Student's t
test and ANOVA with Fisher's least significant difference protected
t test. Statistical significance was accepted at
P<0.05.
| Results |
|---|
|
|
|---|
Dose Response for Chemical Preconditioning in Male Mice
For a 1-hour interval between in vivo treatment and
preparation of slices, a dose-response curve was obtained in male mice
(Figure 1
). In C slices from males, PSA
recovered to 33±23% (mean±SD) of onset on 15 minutes of
hypoxia. Posthypoxic recovery of PSA was 59±31%
(P<0.05) with 5 mg/kg 3NP, 41±24% (P=NS) with
10 mg/kg, 82±32% (P<0.01) with 20 mg/kg, and 64±40%
(P=NS) with 40 mg/kg.
|
Primary and Induced Hypoxic Tolerance During Estrus Cycle
During proestrus, posthypoxic recovery of PSA was 17±12%
(mean±SD; P=NS versus C slices from males). Similarly,
posthypoxic recovery of PSA was 43±23% (P=NS versus C
slices from males) during estrus. In contrast, PSA recovered to 6
±44% in C slices during diestrus (P<0.05 versus C slices
from males) (Figure 2
).
|
In slices prepared from animals pretreated in vivo with a single
intraperitoneal injection of 3-NP (3NP slices), at
a dose of 20 mg/kg an increase of posthypoxic recovery of PSA compared
with controls was observed during proestrus. PSA increased to 57±36%
(P<0.05 versus male 3NP slices; P<0.05 versus C
slices during proestrus). In contrast, posthypoxic recovery of PSA
declined during estrus to 33±12% (P<0.01 versus 3NP
slices from males). During diestrus no difference was observed between
recovery due to primary hypoxic tolerance and recovery after induction
of hypoxic tolerance (60±50%; P=NS versus C slices during
estrus; P=NS versus C slices from males) (Figure 3
).
|
NADH During Hypoxia and Recovery
During proestrus, NADH fluorescence at the end of 15
minutes of hypoxia was 212±76% (mean±SD; P<0.01)
in C slices at the end of hypoxia and 48±34%
(P<0.01) after 30 minutes of recovery. In 3NP slices,
hypoxic NADH increased to 133±11% (P<0.01 versus C slices
during proestrus) and decreased to 69±14% after 30 minutes of
recovery (Figure 4
, top).
|
Corresponding to a decreased posthypoxic recovery of synaptic
transmission, the increase of NADH fluorescence at the end of
hypoxia was 132±7% during estrus, with a posthypoxic recovery
to 88±5%. After preconditioning pretreatment, hypoxic NADH increased
to 149±26%, with a posthypoxic recovery of 58±12%
(P<0.01 versus C slices during estrus) (Figure 4
, bottom).
During diestrus, no significant difference was observed between C
slices (increase to 171±62%; recovery to 59±29%) and 3NP slices
(increase to 123±12%; recovery to 79±11%) (Figure 4
).
ASA Increases Hypoxic Tolerance
Increase of hypoxic tolerance by ASA was investigated in
slices from male mice and slices from female mice during proestrus.
With a 6-hour time interval between in vivo treatment and preparation
of slices, PSA in slices prepared from animals pretreated in vivo with
a single intraperitoneal injection of ASA (ASA
slices) from male mice recovered to 75±36% (mean±SD;
P<0.01 versus control) of onset and to 48±34% in ASA
slices from females during proestrus (P<0.05 versus C
slices proestrus; P<0.05 versus ASA slices from males)
(Figure 5
).
|
| Discussion |
|---|
|
|
|---|
One possible mechanism could be that estradiol potentiates kainate-induced currents.27 It is well established that glutamate plays an important role in hypoxic/ischemic brain injury.14 28 High levels of endogenous estrogens may therefore increase glutamate toxicity during estrus.
Chemical preconditioning is a recently developed experimental strategy16 17 that increases primary hypoxic tolerance. Recent reports suggest that chemical preconditioning may, like ischemic preconditioning during coronary angioplasty,19 be in clinical use already,20 although unknowingly. Like most other experimental strategies against cerebral hypoxia/ischemia, whether this protective strategy is sex dependent has not been tested. The present results show that hypoxic tolerance of females can be significantly increased during stages of the estrus cycle in which females are most vulnerable against hypoxia, ie, during proestrus. During other stages of the estrus cycle, however, that is, during estrus and during diestrus, preconditioning treatment resulted in no benefit.
It has been shown that estradiol antagonizes endogenous adenosine.29 Adenosine is a neuromodulatory peptide that repeatedly has been show to be protective against hypoxia. Recently, it has also been shown that adenosine agonists simulate preconditioning30 and are partial agonists at KATP channels.31 It might therefore be speculated that chemical preconditioning and activation of KATP channels are particularly useful in situations in which the protective effects of adenosine are antagonized by endogenous estrogen and need to be overcome by preconditioning pretreatment.
Interestingly, the increase of cellular hypoxic tolerance by ASA may help to explain that protection in secondary stroke prevention is sex dependent,21 although there is no sex-related difference in the effect of ASA on platelet aggregation.22 In the present study it was shown that the benefit of ASA is greater for females during proestrus than for males. While chemical preconditioning is of some protection in females, treatment benefit seems to be greater in males than in females.
One of the mechanisms partaking in increased hypoxic tolerance is preservation of high-energy phosphates during hypoxic energy metabolism16 and an attenuated increase of NADH during hypoxic hypoxia.17 A difference in oxidative energy metabolism also accounts for part of the variability of primary and induced hypoxic tolerance during the estrus cycle. In fact, this study demonstrates that an improved recovery of electrophysiological function, which is a good indicator of slice integrity,32 correlates with a reduced hypoxic increase of NADH. In this study it is shown that the reverse is also true. When the hypoxic NADH increase becomes larger because of a preceding treatment (eg, on pretreatment during estrus), recovery of PSA becomes smaller.
We conclude that primary hypoxic tolerance depends on the estrus cycle in females. Increase of hypoxic tolerance by preconditioning treatment also depends on the estrus cycle and warrants further investigation of the detailed mechanisms. Part of the differential sensitivity is mediated by differences in hypoxic oxidative energy metabolism. Further investigations of experimental and clinical therapeutic strategies against cerebral ischemia/hypoxia need to consider the differences in males and females.
| Acknowledgments |
|---|
Received February 3, 1999; revision received March 17, 1999; accepted March 23, 1999.
| References |
|---|
|
|
|---|
School of Public Health, University at Albany, Rensselaer, New York
| Introduction |
|---|
|
|
|---|
The article by Kasischke et al demonstrates that tolerance to cerebral hypoxia is gender dependent, as would be expected from previous studies. Beyond this observation the authors demonstrate 2 important new observations, both of which have potential clinical significance for treatment of stroke patients. Chemical preconditioning through use of 3-nitropropionate, an inhibitor of succinic dehydrogenase, acts similar to hypoxic preconditioning to promote increased tolerance to ischemia. In this study, the authors have shown that such chemical preconditioning works in males but in females is effective only during proestrus, not during estrus and diestrus. The latter observation is important, because proestrus is the period of greatest ischemic vulnerability. They also demonstrate that the known beneficial effects of acetylsalicylic acid on ischemia is greater in females than males.
Optimal treatment of patients with disease is complex. Drugs are differentially effective at different times of the day, depending on circadian and other rhythms. These studies, in conjunction with others, clearly show that male/female differences and differences in the stage of the menstrual cycle must be considered in design of optimal therapy for ischemic brain disease.
Received February 3, 1999; revision received March 17, 1999; accepted March 23, 1999.
This article has been cited by other articles:
![]() |
Xiantang Li, M. R. Elwell, A. M. Ryan, and R. Ochoa Morphogenesis of Postmortem Hepatocyte Vacuolation and Liver Weight Increases in Sprague-Dawley Rats Toxicol Pathol, October 1, 2003; 31(6): 682 - 688. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |